| P50 | author | Henk-Jan Guchelaar | Q63658803 |
| P2093 | author name string | van den Berg LH | |
| | Groeneveld GJ | |
| | Lie-A-Huen L | |
| | van Kan HJ | |
| P2860 | cites work | Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis | Q24678827 |
| | El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis | Q29619074 |
| | A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis | Q31115246 |
| | Pharmacogenetics and adverse drug reactions | Q34088287 |
| | A clinical trial of creatine in ALS. | Q40469445 |
| | Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS. | Q40679805 |
| | Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes | Q40776960 |
| | Voltage-activated sodium currents in a cell line expressing a Cu,Zn superoxide dismutase typical of familial ALS. | Q40987920 |
| | Natural history of ALS: symptoms, strength, pulmonary function, and disability | Q41152646 |
| | The pharmacology and mechanism of action of riluzole | Q41263084 |
| | MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring | Q43420119 |
| | A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 |
| | Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. | Q44634164 |
| | Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial | Q46886269 |
| | Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. | Q50920500 |
| | Impact of random and fixed (optimal) sampling approach on the Bayesian estimation of clearance. | Q54702416 |
| | A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. | Q55034186 |
| | Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II | Q71177245 |
| | A comparison of three measures of disease progression in ALS | Q71741635 |
| | A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group | Q72759362 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| | serum concentration | Q126107668 |
| P304 | page(s) | 718-722 | |
| P577 | publication date | 2007-09-26 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | An association study of riluzole serum concentration and survival and disease progression in patients with ALS | |
| P478 | volume | 83 | |